Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2020-04-06 Annual Report
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Annual Report 2019
Annual Report Classification · 100% confidence The document is titled '2019 ÅRSREDOVISNING' (2019 Annual Report) and contains comprehensive sections including a management report, financial statements (income statement, balance sheet, cash flow), notes, and an auditor's report. It covers the full fiscal year 2019 and provides detailed business and financial performance analysis, fitting the definition of an Annual Report (10-K). FY 2019
2020-04-06 Swedish
Annual Report 2019
Annual Report Classification · 100% confidence The document is explicitly titled '2019 ANNUAL REPORT' and contains comprehensive sections including the CEO's message, business strategy, operational highlights, financial statements (Income Statements, Balance Sheets, Cash Flow), accounting principles, and an auditor's report. It is a full-length annual report for the fiscal year 2019, not an announcement or a summary. FY 2019
2020-04-06 English
Kallelse till årsstämma i Medivir AB (publ)
AGM Information Classification · 100% confidence The document is titled "Kallelse till årsstämma i Medivir AB (publ)" which translates to "Notice of Annual General Meeting in Medivir AB (publ)". It details the date, time, location, participation rules, and the proposed agenda for the meeting. The agenda items (points 1 through 19) cover standard AGM topics like election of the chairman, approval of the agenda, presentation of the annual report, decisions on results, election of directors and auditors, and proposals regarding remuneration guidelines and amendments to the articles of association. This content directly corresponds to the purpose of an Annual General Meeting (AGM) notice and related materials. Therefore, the classification is AGM-R.
2020-04-06 Swedish
Notice of Annual General Meeting of Medivir AB (publ)
AGM Information Classification · 100% confidence The document is explicitly titled "Notice of Annual General Meeting of Medivir AB (publ)" and details the date, location, participation requirements, proposed agenda items (including elections, approval of reports, remuneration, and share issues), and specific proposals related to the meeting's proceedings. This content perfectly matches the definition of materials shared during an Annual General Meeting (AGM). Therefore, the correct classification is AGM-R.
2020-04-06 English
Första patienten med levercancer doserad i Medivirs fas Ib-studie med MIV-818
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing that the first patient has been dosed in the Phase Ib study for their drug MIV-818 for liver cancer. It details the study design (Phase Ia results, Phase Ib plan), quotes the CEO, and provides background information on liver cancer and the drug. Crucially, it includes a statement about public disclosure under the EU Market Abuse Regulation and a specific date/time stamp ("den 10 mars 2020, kl 08.55"). This structure is characteristic of an official regulatory announcement or press release regarding clinical trial progress, which often falls under general regulatory filings or specific announcements if they relate to material events. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a specific management/board change (MANG), the most appropriate general category for a material clinical update that is not a formal financial filing is Regulatory Filings (RNS), as it is a mandatory public disclosure of a material event. Alternatively, given the focus on clinical trial progress, it could sometimes be classified as 'LTR' (Legal/Regulatory/Trial Update), but RNS is the standard catch-all for non-financial, mandatory disclosures like this in many databases when a more specific clinical trial update code is unavailable. Given the options, RNS is the best fit for a general regulatory announcement of a clinical milestone.
2020-03-10 Swedish
First liver cancer patient dosed in the MIV-818 phase Ib study
Regulatory Filings Classification · 92% confidence The document is a press release from Medivir AB announcing that the first patient has been dosed in a Phase Ib study for their drug MIV-818 for liver cancer. It details the study objectives (safety, tolerability, efficacy) and provides background information on liver cancer and the drug. This type of announcement, focusing on clinical trial progress and scientific updates, is typically classified as an Investor Presentation (IP) if it were a detailed deck, or often falls under general Regulatory Filings (RNS) or sometimes an Earnings Release (ER) if tied to quarterly results. However, since it is a specific, non-financial, clinical trial update announcement, and does not fit the definitions for ER (key highlights only), CT, or AR (standalone audit reports), the most appropriate category for a specific clinical trial progress announcement that is not a formal regulatory filing like a 10-K or a general RNS is often the Investor Presentation (IP) category, as these updates are crucial for investor communication regarding pipeline progress. Given the options, and recognizing this is a specific scientific/pipeline update, IP is a strong candidate, but RNS is the safest fallback for non-standard announcements. Since it is a specific announcement about a clinical trial milestone, and not a general regulatory filing, I will lean towards the category that covers investor-focused updates on pipeline progress, which often overlaps with IP, but given the structure (a press release), RNS (Regulatory Filings/General Announcement) is the most common bucket for such specific, non-periodic corporate news that isn't explicitly about management, dividends, or capital structure. Given the context of a clinical trial update, and lacking a specific 'Clinical Trial Update' code, RNS is the best fit as a general regulatory/corporate announcement.
2020-03-10 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.